Integrating genetic testing and polygenic risk scoring into clinical practice enables precision-medicine strategies that align therapy to disease mechanism, prioritizing APOC3/ANGPTL3 inhibitors in FCS and combined TG-lowering and metabolic therapies in MCS, reducing pancreatitis recurrence, mitigating liver disease progression, and improving long-term cardiometabolic outcomes. Here, ANGPTL3 is linked to liver disorder.